Investieren in die Zukunft von morgen.
Seite 7 von 229 Neuester Beitrag: 23.05.11 20:13 | ||||
Eröffnet am: | 25.06.09 04:47 | von: brunneta | Anzahl Beiträge: | 6.709 |
Neuester Beitrag: | 23.05.11 20:13 | von: buddikatze | Leser gesamt: | 438.145 |
Forum: | Hot-Stocks | Leser heute: | 64 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 4 | 5 | 6 | | 8 | 9 | 10 | ... 229 > |
Ihr dürftet es nicht vergessen das hier auch viele Zocker drin sind.
Deswegen Geduld und Vernunft bringt uns weiter.
Aber ich bin zuversichtlich und hoffe wenn es los geht dann ziemlich schnell hoch.
vorbei
bis denne
Gekauft wird in Berlin fleisig zu 0,003€
Schmeißt ihr immer gerne 30% aus dem Fenster??
http://twitter.com/cbai
http://www.ariva.de/cord_blood_amer_inc-aktie
bei den Beträgen kann das schon mal vorkommen
$1.6 Million in Debt Retired in Third Quarter 2009
Tuesday August 25, 2009, 5:00 am EDT
SANTA MONICA, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
"We have said that one of the pillars of strength for Cord Blood America in 2009 was to significantly reduce debt and we certainly are fulfilling this obligation to our shareholders," said Matthew Schissler, founder and CEO. The Company also announced on August 5, 2009, that it retired $2.53 million of long-term debt with the payoff of two notes with the Shelter Island Opportunity Fund.
"Retirement of debt is good for our balance sheet and makes CBAI a better investment for our shareholders," said Mr. Schissler. "We are pleased with a strengthened balance sheet, having recently announced second quarter results showing a significant increase in working capital and cash on hand."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
sogar auf you tube.
gut invest an alle
Um an die richtigen " Mücken " zu kommen, sehe ich momentan folgende Papiere in meiner persönlichen Hitliste - keine Kaufempfehlung, nur eine nüchterne Betrachtung:
iq power : ist seriös, Zukunft gesichert, in 2 Jahren brummt der Laden wieder. Und momentan ist die Aktie sehr günstig ! 5 fach in einem Jahr möglich
cord blood: ist seriös, Zukunft gesichert und aussichtsreich, Aktie mega günstig. Kurs nach oben hin offen, alles ist möglich ! Aber es bedarf schon eine gewisse Zeit; das wird wohl noch 10 Jahre dauern, wenn man den Jackpot knacken will !
ecotality: seriös ? naja. Zukunft interessant. Momentan zu teuer. Aber bei 3 cent würde ich da reinbuttern . Hohes Risiko, aber bei 3 cent wird ne spitzen Chance geboten !
BKN biostrom: seriös ; Geld ist genug da; Zukunft soll spitze werden; Ab 1,80 kaufe ich diese Aktie wie Sau ! 5-fach in 2 Jahren möglich. Aber ansonsten eine recht sichere Anlage, da keine Aussicht auf Totalverlust, bzw. keine massiven Kursrütsche mehr.
Für weitere Vorschläge bin ich immer offen !
Los Brunetta, hau noch ein paar raus !
Mal abwarten ;)
Es wird noch zu steigerung kommen
http://www.4investors.de/php_fe/index.php?sektion=stock&ID=22579
Thursday, 10 September 2009 06:00 Cord Blood America, Inc.
SANTA MONICA, Calif., Sept. 10 - Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, said today that it is on schedule to complete the construction of its new Las Vegas laboratory by the first week of October.
Matthew Schissler, founder and CEO, was interviewed by analyst Francis Gaskins. The entire interview is available at http://www.stoxrox.com/cbai-9-10-09.mp3 .
"Most of the equipment has been purchased and we are scheduled to begin processing our own stem cells in the near future," Mr. Schissler said in the interview. He said the new laboratory will:
Allow gross profit to increase greatly because the Company will no longer outsource and pay significant storage fees.
Allow Cord Blood to store tissues and samples for other companies.
Decrease transportation costs because the lab is near the large Las Vegas airport.
Allow for the storage of other stem cells such as adipose tissue and peripheral blood stem cells.
Prepare the Company for the future, with more medical uses of stem cells expected every year.
"This facility will perhaps be the largest cryogenic storage lab in the U.S. We believe adding business-to-business clients, and diversifying our income stream, will provide immediate returns for shareholders," Mr. Schissler said.
In the interview, Cord Blood America's CEO said $6.6 million in debt has been eliminated from the balance sheet so far this year and "we will continue to reduce debt as far and fast as possible. Shareholders should understand that once the debt is gone, the true valuation of the Company will emerge."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
Quelle: http://www.cordblood-america.com/Cord-Blood-America-News/cor…